Trials / Active Not Recruiting
Active Not RecruitingNCT07115576
Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 106 (estimated)
- Sponsor
- Hue University of Medicine and Pharmacy · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Title: Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: A Prospective Study Purpose: The goal of this clinical trial is to learn if single-session radiofrequency ablation (RFA) can effectively reduce the volume of benign thyroid nodules in adults. It will also evaluate the safety of the RFA procedure. The main questions it aims to answer are: 1. Does RFA procedure reduce the size of thyroid nodules (measured by volume reduction rate - VRR)? 2. What medical problems or complications do participants experience after undergoing RFA? 3. How does RFA affect thyroid hormone levels (TSH, FT4)? 4. Is RFA equally effective in purely cystic nodules, solid nodules, and predominantly cystic nodules? Comparator: This is a single-arm study, so there is no placebo or comparison treatment group. All participants will undergo RFA, and the results will be assessed over time. Participants will: * Undergo one session of RFA for benign thyroid nodules. * Be followed up with clinical visits and ultrasound assessments at 1, 6, and 12 months. * Have thyroid hormone levels tested and nodule size measured by ultrasound at each follow-up. * Be monitored for any side effects or complications such as voice changes, pain, or bleeding.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Radiofrequency ablation alone | Radiofrequency ablation (RFA) is a minimally invasive procedure used to treat benign thyroid nodules without surgery. It involves inserting a thin, needle-like electrode into the nodule under ultrasound guidance. Using high-frequency alternating current, the electrode generates heat to destroy targeted thyroid tissue, causing the nodule to shrink over time. |
Timeline
- Start date
- 2023-02-10
- Primary completion
- 2026-02-10
- Completion
- 2026-04-10
- First posted
- 2025-08-11
- Last updated
- 2025-12-16
Locations
1 site across 1 country: Vietnam
Source: ClinicalTrials.gov record NCT07115576. Inclusion in this directory is not an endorsement.